Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D Cohen

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Cancer Immunology Research|August 22, 2019
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple MyelomaTatiana Pazina, Ashley M James, Kimberly B Colby, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Plos One|May 11, 2010
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulationAdam D Cohen, David A Schaer, Cailian Liu, et al.
Haematologica|August 28, 2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myelomaHanny Musa, Michał Mielnik, Suzanne Trudel, et al.
British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.
JCI Insight|October 22, 2021
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitnessDaniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, et al.
Blood Advances|February 24, 2026
Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myelomaHeta Patel, Harper Hubbeling, Kyle Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple MyelomaSikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
Blood Advances|December 12, 2025
Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaHeta Patel, Harper Hubbeling, Kyle L Yu, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Cancer Immunology Research|August 22, 2019
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple MyelomaTatiana Pazina, Ashley M James, Kimberly B Colby, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Plos One|May 11, 2010
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulationAdam D Cohen, David A Schaer, Cailian Liu, et al.
Haematologica|August 28, 2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myelomaHanny Musa, Michał Mielnik, Suzanne Trudel, et al.
British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.
JCI Insight|October 22, 2021
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitnessDaniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, et al.
Blood Advances|February 24, 2026
Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myelomaHeta Patel, Harper Hubbeling, Kyle Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple MyelomaSikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
Blood Advances|December 12, 2025
Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaHeta Patel, Harper Hubbeling, Kyle L Yu, et al.
Pageof 11